青春期矮身材儿童身高改善的药物治疗  

Pharmacological therapies for height improvement in pubertal children with short stature

作　　者：朱建芳[1] 王春林[1] ZHU Jian-Fang;WANG Chun-Lin(Department of Pediatrics,First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310003,China)

机构地区：[1]浙江大学医学院附属第一医院儿科,浙江杭州310003

出　　处：《中国当代儿科杂志》2024年第2期118-123,共6页Chinese Journal of Contemporary Pediatrics

摘　　要：青春期矮身材可严重影响青少年的身心健康。青春期由于性激素导致的骨龄持续加速进展,限制了生长所需的时间,是矮身材治疗的巨大挑战,至今仍无标准化的治疗方案。青春期也是改善成年终身高的最后机会。目前临床常用治疗药物主要有重组人生长激素、促性腺激素释放激素类似物和第三代芳香化酶抑制剂。近年来,以改善成年终身高为目的的个体化治疗成为临床关注的重点。该文对青春期矮身材儿童身高改善的药物治疗相关研究进行梳理总结,为临床医生提供参考.Short stature in puberty significantly affects the physical and mental health of adolescents.The continuous acceleration of skeletal maturation,caused by sex hormones during puberty,limits the time available for growth and poses a considerable challenge for the treatment of short stature.To date,there is still no standardized treatment protocol for this disorder.However,puberty is the last period to improve the final adult height.Currently,commonly used pharmacological treatments in clinical settings include recombinant human growth hormone,gonadotropin-releasing hormone analogs,and third-generation aromatase inhibitors.In recent years,personalized treatment aiming to improve the final adult height has become a key focus in clinical practice.This article provides a comprehensive summary of research on pharmacological therapies for height improvement in pubertal children with short stature,offering valuable insights for healthcare professionals.

关 键 词：矮身材 重组人生长激素 促性腺激素释放激素类似物 芳香化酶抑制剂 青春期 

分 类 号：R725.8[医药卫生—儿科]